Beta Drugs
- Market cap
- ₹ 2,100 Cr.
- P/E
- 42.3x
- P/B
- 8.16x
- 52-week range
- 990.1 – 2,807.9
- ROE
- 19%
- ROCE
- 19%
- Dividend yield
- 0%
- Debt / equity
- 0.61
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE
About
Beta Drugs Limited is an India-based oncology medicine manufacturing company. The Company specializes in the intricate field of complex chemical synthesis for anti-cancer bulk drugs and finished dosages. The Company operates through one segment, Pharmaceuticals. Its product category includes cosmeceutical products and oncology products. The cosmeceutical products include La’Thrix, BACINOX, URTICALM, HUMIDA, NUSPLASH, UVIREX, ADVIBE, SENSIBAR, and RECAPRO. The oncology products include Temozad(Temozolomide), ADVIN(Vinorelbine), ADSIDE(Etoposide), ADRIB(Doxorubicin), ADCOV(Leucovorin calcium), ADPLATIN(Oxaliplatin), INOTAD(Irinotecan), ADCIST(Cisplatin), ADCARB(Carboplatin), ERLOTAD(Erlotinib), ADOXI(Docetaxel), AMGICIN(Gemcitabine), ADPAXIL(Paclitaxel), ADMIDE(Bicalutamide), and others. The Company's subsidiaries include Adley Lab Limited and Adley Formulations Private Limited.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Beta Drugs against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)42.3 against a typical 34.6: pricier than most peers (1st = cheapest).138th of 220
- Sales growth+33% against a typical +15.6% from a year earlier.51st of 197
- Profit growth+58.3% against a typical +18.9% from a year earlier.45th of 160
- Share price, 3 months−12% against a typical −0.5%.155th of 200
- Size₹ 2,100.3 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).69th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Moderate safety, with caution
Rated A- to BBB+ by 2 agencies- All agencies agree and none has raised a warning.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| Brickwork | BWR A- | Stable | 6 Jul 2026 |
| CRISIL | Crisil BBB+ | Positive | 20 Jan 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 6 Jul 2026 | Rating action | BWR A- | — | Brickwork | ₹ 37.89 Cr. | |
| 20 Jan 2026 | Reaffirmed | Crisil BBB+ | — | CRISIL | ₹ 8 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 22 Oct 2026 | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 3 Sep 2026 | Other business matters | To consider other business matters |
| 20 Jul 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 14 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 14 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 9 Jan 2026 | Other business matters | To consider other business matters (a) acquisition of equity shares of a target company from certain shareholders of the target company; (b) issue certain equity shares to the shareholders of the target company on a preferential basis through the private placement route, as consideration other than cash in lieu of the acquired shares and(c) to consider and approve the Employee Stock Option Plan (ESOP). |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 88 | 94 | 100 | 103 | 87 | 94 | 126 | 137 |
| Expenses | 70 | 76 | 81 | 82 | 70 | 76 | 98 | 107 |
| Operating Profit | 18 | 17 | 20 | 21 | 17 | 18 | 27 | 30 |
| OPM % | 21% | 18% | 20% | 21% | 19% | 19% | 22% | 22% |
| Other Income | −1 | 2 | 3 | 3 | 2 | 3 | 2 | 2 |
| Interest | 2 | 3 | 3 | 4 | 4 | 4 | 3 | 2 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 4 | 5 |
| Profit before tax | 12 | 12 | 16 | 16 | 10 | 12 | 22 | 26 |
| Tax % | 25% | 26% | 25% | 26% | 19% | 24% | 25% | 25% |
| Net Profit | 9 | 9 | 12 | 12 | 9 | 9 | 16 | 19 |
| EPS in Rs | 8.86 | 8.95 | 11.59 | 12.11 | 8.4 | 8.93 | 14.25 | 16.68 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 27%
- 3 Years
- 19%
- TTM
- 15%
- 10 Years
- —
- 5 Years
- 29%
- 3 Years
- 11%
- TTM
- 15%
- 10 Years
- —
- 5 Years
- 28%
- 3 Years
- 29%
- TTM
- —
- 10 Years
- —
- 5 Years
- 25%
- 3 Years
- 23%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Beta Drugs | ₹ 1,965.00 | ₹ 2,100 Cr. | 42.3x | 8.2x | 19% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Rahul Batra
- Chairman of the Board, Managing Director
- Nipun Arora
- Chief Financial Officer
- Rajni Brar
- Chief Compliance Officer, Company Secretary
- Varun Batra
- Joint Managing Director, Whole Time Director
- Ashutosh Shukla
- Whole Time Director
- Balwant Singh
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.